Investor Presentation for third quarter and nine months ended on 31 December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories reported Q3 FY26 revenue of Rs 1,229 lacs, down 3% year-on-year, while 9M FY26 revenue fell 4.75% to Rs 3,607 lacs due to planned rationalization of low-margin businesses. Despite the revenue dip, EBITDA rose 8% in Q3 to Rs 125 lacs and 6.8% in 9M FY26, with EBITDA margin expanding to 10.16% from 9.13% in Q3, driven by better cost control and operational efficiency. However, net profit declined 27% in Q3 to Rs 74 lacs and 13% over 9M FY26, weighed down by higher depreciation or tax impact. Management, led by CEO Aalap Prajapati, reiterated focus on brand-led growth, field productivity, and sustained margin expansion. The company remains self-funded with no debt concerns highlighted, supported by 8 leading brands, 150 medical representatives, and presence across 13 states.
Mixed signals for shareholders — revenue contraction alongside margin expansion suggests management is sacrificing top-line growth for profitability, but the sharp 27% drop in Q3 net profit may weigh on near-term sentiment despite the strategic rationale.